Display options
Cite
Johannsson G, Bidlingmaier M, Biller BMK, et al. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocr Connect. 2018;7(3):R126-R134doi: 10.1530/EC-18-0047.
Johannsson, G., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Casanueva, F. F., Chanson, P., Clayton, P. E., Choong, C. S., Clemmons, D., Dattani, M., Frystyk, J., Ho, K., Hoffman, A. R., Horikawa, R., Juul, A., Kopchick, J. J., Luo, X., Neggers, S., Netchine, I., Olsson, D. S., Radovick, S., Rosenfeld, R., Ross, R. J., Schilbach, K., Solberg, P., Strasburger, C., Trainer, P., Yuen, K. C. J., Wickstrom, K., Jorgensen, J. O. L. (2018). Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine connections, 7(3), R126-R134. https://doi.org/10.1530/EC-18-0047
Johannsson, Gudmundur, et al. "Growth Hormone Research Society perspective on biomarkers of GH action in children and adults." Endocrine connections vol. 7,3 (2018): R126-R134. doi: https://doi.org/10.1530/EC-18-0047
Johannsson G, Bidlingmaier M, Biller BMK, Boguszewski M, Casanueva FF, Chanson P, Clayton PE, Choong CS, Clemmons D, Dattani M, Frystyk J, Ho K, Hoffman AR, Horikawa R, Juul A, Kopchick JJ, Luo X, Neggers S, Netchine I, Olsson DS, Radovick S, Rosenfeld R, Ross RJ, Schilbach K, Solberg P, Strasburger C, Trainer P, Yuen KCJ, Wickstrom K, Jorgensen JOL. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocr Connect. 2018 Mar;7(3):R126-R134. doi: 10.1530/EC-18-0047. Epub 2018 Feb 26. PMID: 29483159; PMCID: PMC5868631.
Copy Download .nbib Format: NLM
Share it on

Endocr Connect. 2018 Mar;7(3):R126-R134. doi: 10.1530/EC-18-0047. Epub 2018 Feb 26.

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults.

Endocrine connections

Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen,

Affiliations

  1. Department of Internal Medicine and Clinical NutritionSahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  2. Medizinische Klinik und Poliklinik IVKlinikum der Universität München, Munich, Germany.
  3. Neuroendocrine UnitMassachusetts General Hospital, Boston, Massachusetts, USA.
  4. Federal University of ParanaCuritiba, Brazil.
  5. Department of MedicineComplejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
  6. Assistance Publique-Hôpitaux de Parisand Inserm, Paris, France.
  7. Developmental Biology & MedicineFaculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.
  8. Department of EndocrinologyPrincess Margaret Hospital & School of Medicine, University of Western Australia, Western Australia, Australia.
  9. Department of MedicineUniversity of North Carolina, Chapel Hill, North Carolina, USA.
  10. Great Ormond Street Institute of Child HealthLondon, UK.
  11. Department of EndocrinologyOdense University Hospital, Odense, Denmark.
  12. Princess Alexandra Hospital and University of QueenslandBrisbane, Australia.
  13. Department of MedicineStanford University and VA Palo Health Care System, Palo Alto, California, USA.
  14. National Center for Child Health and DevelopmentTokyo, Japan.
  15. Department of Growth and ReproductionRigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  16. Edison Biotechnology Institute and Heritage College of Osteopathic MedicineOhio University, Athens, Ohio, USA.
  17. Department of PediatricsTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  18. Section of EndocrinologyDepartment of Medicine, Pituitary Centre Rotterdam, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  19. Service d'Explorations Fonctionnelles EndocriniennesAP-HP, Hôpital Trousseau, Sorbonne Université, INSERM UMRs 938, Paris, France.
  20. Department of EndocrinologyInstitute of Medicine, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
  21. Rutgers University-Robert Wood Johnson Medical SchoolNew Brunswick, New Jersey, USA.
  22. Department of PediatricsOregon Health Science University, Portland, Oregon, USA.
  23. University of SheffieldSheffield, UK.
  24. Universidade do Estado do Rio de JaneiroRio de Janeiro, Brazil.
  25. Charité-UniversitätsmedizinBerlin, Germany.
  26. The Christie NHS Foundation TrustUniversity of Manchester, Manchester, UK.
  27. Barrow Pituitary CenterBarrow Neurological Institute, Department of Neuroendocrinology, University of Arizona College of Medicine, Phoenix, Arizona, USA.
  28. Medical Products AgencyUppsala, Sweden.
  29. Aarhus University HospitalAarhus, Denmark [email protected].

PMID: 29483159 PMCID: PMC5868631 DOI: 10.1530/EC-18-0047

Abstract

OBJECTIVE: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults and in patients with acromegaly.

PARTICIPANTS: GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry.

EVIDENCE: Current literature was reviewed and expert opinion was utilized to establish the state of the art and identify current gaps and unmet needs.

CONSENSUS PROCESS: Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process.

CONCLUSIONS: The clinical endpoint in paediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH-deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of comorbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly, normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.

© 2018 Growth Hormone Research Society.

Keywords: GH; GH deficiency; IGF-I; acromegaly

References

  1. Clin Pharmacol Ther. 2001 Mar;69(3):89-95 - PubMed
  2. J Clin Endocrinol Metab. 1999 Nov;84(11):3929-35 - PubMed
  3. Health Aff (Millwood). 2005 Jan-Feb;24(1):67-78 - PubMed
  4. J Clin Endocrinol Metab. 1996 Apr;81(4):1371-7 - PubMed
  5. Eur J Endocrinol. 2016 Feb;174(2):P1-9 - PubMed
  6. Stat Med. 2012 Nov 10;31(25):2973-84 - PubMed
  7. BMC Med Inform Decis Mak. 2011 Jun 01;11:38 - PubMed
  8. J Clin Invest. 1983 Feb;71(2):175-82 - PubMed
  9. Clin Chem. 2008 Aug;54(8):1268-76 - PubMed
  10. J Clin Endocrinol Metab. 2013 Jun;98(6):E1072-87 - PubMed
  11. J Clin Endocrinol Metab. 2015 Apr;100(4):1405-11 - PubMed
  12. J Clin Endocrinol Metab. 1998 Feb;83(2):382-95 - PubMed
  13. Horm Res Paediatr. 2017;87(5):324-332 - PubMed
  14. Eur J Endocrinol. 2005 Feb;152(2):165-70 - PubMed
  15. J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51 - PubMed
  16. J Clin Endocrinol Metab. 2000 Apr;85(4):1505-12 - PubMed
  17. J Clin Endocrinol Metab. 2014 Aug;99(8):2917-24 - PubMed
  18. Pituitary. 2016 Feb;19(1):39-49 - PubMed
  19. Growth Horm IGF Res. 2010 Feb;20(1):8-18 - PubMed
  20. Nat Rev Endocrinol. 2014 Apr;10(4):243-8 - PubMed
  21. Clin Endocrinol (Oxf). 2017 Oct;87(4):350-358 - PubMed
  22. Eur J Endocrinol. 2013 Jul 29;169(3):277-89 - PubMed
  23. Annu Rev Pharmacol Toxicol. 2001;41:347-66 - PubMed
  24. Horm Res Paediatr. 2012;78(1):8-17 - PubMed
  25. Horm Metab Res. 2003 Nov-Dec;35(11-12):726-33 - PubMed
  26. Sci Transl Med. 2017 Dec 6;9(419):null - PubMed
  27. Circulation. 2004 May 25;109(20):2405-10 - PubMed
  28. Eur J Endocrinol. 2011 Feb;164(2):157-67 - PubMed
  29. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92 - PubMed
  30. Pituitary. 2017 Dec;20(6):692-701 - PubMed
  31. Eur J Endocrinol. 2018 Jan;178(1):67-76 - PubMed
  32. J Clin Endocrinol Metab. 2010 May;95(5):2089-98 - PubMed
  33. Horm Res Paediatr. 2016;86(6):361-397 - PubMed
  34. Nat Rev Endocrinol. 2015 Dec;11(12):735-46 - PubMed
  35. Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO27-BIO33 - PubMed
  36. J Clin Endocrinol Metab. 2011 Jul;96(7):2089-97 - PubMed
  37. Eur J Endocrinol. 2016 Jun;174(6):C1-8 - PubMed
  38. Clin Endocrinol (Oxf). 2002 Aug;57(2):251-8 - PubMed
  39. N Engl J Med. 2000 Apr 20;342(16):1171-7 - PubMed
  40. Clin Chem. 2011 Apr;57(4):555-9 - PubMed
  41. Am J Physiol Endocrinol Metab. 2003 Jun;284(6):E1149-55 - PubMed
  42. Clin Endocrinol (Oxf). 2014 Jan;80(1):92-100 - PubMed
  43. Growth Horm IGF Res. 2010 Feb;20(1):19-25 - PubMed

Publication Types

Grant support